Published Aug 12, 2026
Alumis Q1 2026: The NDA Nears as Envudeucitinib Posts Best-in-Class Plaque Psoriasis Clearance
In-depth research on ALMS covering the business overview, key financial moves, risk frame, and the bottom-line on what changed since the last report.
3,338 words15 min read
Read report